At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 36 enrolled
Drug / intervention
fluticasone propionate +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Fluticasone Propionate, Azithromycin, and Montelukast Sodium in Treating Patients With Bronchiolitis Obliterans Who Previously Underwent Stem Cell Transplant
In Brief
A Phase 2 clinical trial evaluating fluticasone propionate, montelukast sodium, and 1 other intervention for Bronchiolitis Obliterans. Completed, enrolled 36 participants across 11 sites.
Detailed Summary
This phase II trial studies how well giving fluticasone propionate, azithromycin, and montelukast sodium (FAM) together works in treating patients with bronchiolitis obliterans who previously underwent stem cell transplant. FAM may be an effective treatment for bronchiolitis obliterans
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBronchiolitis Obliterans
CountriesUnited States
CollaboratorsNational Cancer Institute (NCI)
Timeline
Phase 2CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedMar 2011
Enrollment StartJun 2011
Primary CompletionSep 2014
Study CompletionDec 2015
TodayJul 2026
First PostedMar 3, 2011
Enrollment StartJun 1, 2011
Primary CompletionSep 1, 2014
Study CompletionDec 1, 2015
TodayJul 2, 2026
Enrollment to primary: 3.3 yearsPosted 15.3 years ago
Interventions
fluticasone propionatedrug
Given inhaled PO
montelukast sodiumdrug
Given PO
azithromycindrug
Given PO